Executive change and supply concerns refocus attention on Celanese stock
Celanese (CE) has been back on investors radar after commentary around possible Strait of Hormuz disruptions and acetic acid supply tightened the spotlight on its core chemicals exposure and cash flow discipline.
At the same time, the company disclosed that Timothy Go resigned from its Board of Directors on February 27, 2026, with Celanese stating his departure did not stem from any disagreement over operations, policies, or practices.
See our latest analysis for Celanese.
At a share price of $59.60, Celanese has seen momentum build quickly, with a 41.37% year to date share price return and a 37.01% 90 day share price return, in contrast with a 40.49% 3 year total shareholder return decline and a 56.46% 5 year total shareholder return decline.
If this focus on chemicals supply is sharpening your interest in materials names, it could be a good time to scan the 8 top copper producer stocks for other potential opportunities in the space.
With Celanese trading at $59.60 against an average analyst target near $63 and an indicated intrinsic discount of about 41%, you have to ask: is there real value left here, or is the recent optimism already pricing in future growth?
Most Popular Narrative: 15.7% Overvalued
Celanese last closed at $59.60 while the most followed narrative pegs fair value closer to $51.50, which raises questions about how optimistic those underlying forecasts really are.
Celanese's investments in green chemistry and downstream product diversification position it to capture share as demand accelerates for sustainable materials driven by both tightening environmental regulation and increased consumer focus on circular solutions, supporting long-term top-line and margin expansion.
Curious what kind of revenue path and margin rebuild would need to play out to back up that fair value? The narrative leans heavily on a profit swing, steady share count, and a future earnings multiple that sits well below many peers. The real question is how those ingredients fit together over the next few years.
Result: Fair Value of $51.50 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, those upbeat assumptions could unravel if weak acetyl demand and overcapacity linger, or if elevated debt and interest costs squeeze the expected earnings recovery.
Find out about the key risks to this Celanese narrative.
Another angle on value: sales multiple vs fair value
The most followed narrative points to Celanese being about 15.7% overvalued against a fair value of $51.50, yet the current P/S of 0.7x tells a different story. That level sits below the US Chemicals industry at 1x, the peer average at 2.8x, and even the fair ratio of 1.3x. This raises the question of whether the market could move closer to that higher benchmark. For you, the tension is clear: do earnings risks justify this discount to sales, or is sentiment leaning too hard on recent losses?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on value and sentiment running in both directions, this is the moment to look through the data yourself and decide what really matters. To get a fuller picture before you move on, take a quick look at the 3 key rewards and 1 important warning sign that sit behind this story.
Looking for more investment ideas?
Before you move on, give yourself an edge by lining up a few more candidates that match the kind of risk and return profile you actually want.
- Target potential bargains that pair quality fundamentals with discounted prices by scanning the 47 high quality undervalued stocks for ideas that might merit a closer look.
- Prioritise resilience and capital strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (41 results) that could help anchor a more defensive core to your holdings.
- Hunt for opportunities that others may be missing by checking the screener containing 25 high quality undiscovered gems and seeing which names stand out on your criteria.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com